Top cancer drugs paid by Medicare Part B by sales price per dosage 2014

Leading Medicare Part B cancer drugs based on average sales price per dosage in 2014 (in U.S. dollars)

by Statista Research Department, last edited Mar 17, 2016
Top cancer drugs paid by Medicare Part B by sales price per dosage 2014 This statistic displays the leading Medicare Part B cancer drugs based on average sales price per dosage in 2014, in U.S. dollars. The average sales price for one dose (1 mg) of a Denosumab injection totaled 14.45 U.S. dollars. The size and demographic of medical professionals in oncology plays a significant role in the accessibility and quality of cancer care for patients in the United States.
Show more

Leading Medicare Part B cancer drugs based on average sales price per dosage in 2014 (in U.S. dollars)

You need to log in to download this statistic
Register for free
Already a member?
Log in
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Cancer in Italy"
  • Incidence
The most important statistics
  • Screening
  • Mortality
  • Care and treatments
  • Research and fundraising
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.